Takeda Pharmaceutical Company Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TKD.F | TEVA | 1795.TW | 2096.HK | NATCOPHARM.BO | EMCURE.BO | |
|---|---|---|---|---|---|---|
| Market cap | 56.86B | 47.37B | 45.96B | 26.58B | 140.69B | 338.44B |
| P/E (TTM) | — | 67.7 | 12.1 | 15.3 | 9.1 | 33.3 |
| Forward P/E | 20.2 | 13.2 | 7.3 | 11.3 | 20.6 | 23.0 |
| Price/book | 1.3 | 6.1 | 1.9 | 2.4 | 1.6 | 6.8 |
| Dividend yield | 3.24% | — | 1.46% | 1.90% | 0.77% | 0.21% |
| 1-year change | +44.85% | +113.56% | −38.73% | −12.62% | −36.60% | +27.60% |
| Today | +0.39% | −0.56% | −1.99% | −4.51% | +0.08% | +1.60% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All TKD.F news ›Takeda Pharmaceutical Launches Orzeyful in Japan and China
www.marketscreener.com Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Launches Orzeyful in Japan and China Published on 10/15/2026 at 06:16 am EDT
Takeda Pharmaceutical Company Limited: Relative Strength Chart - Stock Japan Exchange
Compare Takeda Pharmaceutical Company Limited with the company of your choice via a Relative Strength chart. Real-time 4502 price, Japan Exchange stock exchange Relative Strength Chart Takeda Pharmaceutical Company Limited All financial…
Takeda Pharmaceutical Company Limited Announces New Phase 3 Head-To-Head Results for Zasocitinib
Published on 09/30/2026 at 02:05 am EDT The study enrolled 606 participants, who received zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily up to week 16. Participants were in the study for up to 25 weeks, which included a…
Takeda Pharmaceutical Company Limited Launches ORZEYFUL In Japan And China For Treatment Of Narcolepsy Type 1
Takeda Pharmaceutical Company Limited announced that ORZEYFUL is now available in Japan and China for the treatment of narcolepsy type 1 , providing first access to clinicians to prescribe treatment... Takeda Pharmaceutical Company Limited…
Takeda Pharmaceutical Company Limited Presents Phase 2/3 IgGNITE Study Results Of Investigational Subcutaneous TAK-881 In Primary Immunodeficiency Disease At ESID 2026
Published on 10/14/2026 at 09:37 am EDT 11.9 g/L) were above accepted protective thresholds against infections. Delivering equivalent bodyweight-adjusted IG dosing in a concentrated 20% solution reduced total infusion volume by 50%. This…
Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $20.74, Implies 9% Upside
TradingView Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $20.74, Implies 9% Upside - According to estimates from 14 analysts, Takeda Pharmaceutical Company Limited stock's average price target has risen from…
Bristol Myers Squibb (NYSE:BMY) vs. Takeda Pharmaceutical (NYSE:TAK) Head-To-Head Analysis
Posted by Defense World Staff on Oct 8th, 2026 Takeda Pharmaceutical (NYSE:TAK – Get Free Report) and Bristol Myers Squibb (NYSE:BMY – Get Free Report) are both large-cap healthcare companies, but which is the superior investment? We will…
Takeda Pharmaceuticals' Psoriasis Pill Zasocitinib
Takeda Pharmaceuticals’ experimental psoriasis pill, zasocitinib, outperformed Bristol Myers Squibb’s Sotyktu in a phase 3 trial. Takeda purchased zasocitinib from Nimbus in 2022 for $4 billion ... Takeda Pharmaceuticals' Psoriasis Pill…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com4
-
defenseworld.net1
-
themarketsdaily.com1
-
tradingview.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.